Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.20)
# 2,802
Out of 5,124 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $26.15 | -23.52% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $21.30 | -29.58% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $11.39 | -29.76% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $24.97 | +100.24% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $135.99 | +0.01% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.56 | +143.90% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.10 | +581.32% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.60 | +650.00% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $21.07 | +417.32% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.98 | +304.04% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.87 | +158.40% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $16.11 | +520.73% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $25.00 | -76.00% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $5.22 | +302.30% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $175.20 | -86.87% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $43.20 | -16.67% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $26.15
Upside: -23.52%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $21.30
Upside: -29.58%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $11.39
Upside: -29.76%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $24.97
Upside: +100.24%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $135.99
Upside: +0.01%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.56
Upside: +143.90%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.10
Upside: +581.32%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.60
Upside: +650.00%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $21.07
Upside: +417.32%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.98
Upside: +304.04%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.87
Upside: +158.40%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $16.11
Upside: +520.73%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $25.00
Upside: -76.00%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $5.22
Upside: +302.30%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $175.20
Upside: -86.87%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $43.20
Upside: -16.67%